Volume 66, Issue 2, Pages (August 2014)

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

Volume 62, Issue 3, Pages (September 2012)

Volume 155, Issue 3, Pages (March 1996)

The PSA Era is not Over for Prostate Cancer

Volume 70, Issue 5, Pages (November 2016)

Volume 50, Issue 1, Pages (July 2006)

The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis Urol Int 2017;99:

Volume 58, Issue 2, Pages (August 2010)

Volume 47, Issue 4, Pages (April 2005)

Testosterone Therapy in Men With Prostate Cancer

Volume 69, Issue 5, Pages (May 2016)

Volume 53, Issue 4, Pages (April 2008)

Volume 52, Issue 5, Pages (November 2007)

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Volume 49, Issue 2, Pages (February 2006)

Volume 74, Issue 2, Pages (August 2018)

Volume 53, Issue 5, Pages (May 2008)

Volume 69, Issue 1, Pages (January 2016)

Volume 70, Issue 4, Pages (October 2016)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Volume 51, Issue 5, Pages (May 2007)

Volume 52, Issue 4, Pages (October 2007)

Volume 63, Issue 6, Pages (June 2013)

Volume 59, Issue 2, Pages (February 2011)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 1, Pages (July 2018)

Volume 65, Issue 3, Pages (March 2014)

High Dose Rate Brachytherapy of Localized Prostate Cancer

Volume 60, Issue 4, Pages (October 2011)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 53, Issue 4, Pages (April 2008)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Prostate Cancer Detection: A View of the Future

Volume 68, Issue 3, Pages (September 2015)

Volume 67, Issue 3, Pages (March 2015)

Volume 71, Issue 5, Pages (May 2017)

Volume 70, Issue 5, Pages (November 2016)

Volume 71, Issue 6, Pages (June 2017)

Localised and Locally Advanced Prostate Cancer: Who to Treat and How?

Volume 73, Issue 4, Pages (April 2018)

The PSA Era is not Over for Prostate Cancer

Yuanshan Cui, Yong Zhang European Urology

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Volume 53, Issue 4, Pages (April 2008)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 2, Pages (August 2018)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Volume 71, Issue 3, Pages (March 2017)

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 59, Issue 4, Pages (April 2011)

Volume 70, Issue 1, Pages (July 2016)

Volume 75, Issue 4, Pages (April 2019)

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Volume 68, Issue 5, Pages (November 2015)

Volume 74, Issue 6, Pages (December 2018)

European Urology Oncology

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Volume 53, Issue 6, Pages (June 2008)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 52, Issue 1, Pages (July 2007)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Axel Heidenreich European Urology Supplements

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 66, Issue 2, Pages 243-250 (August 2014) Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 Trial Thomas Wiegel, Detlef Bartkowiak, Dirk Bottke, Claudia Bronner, Ursula Steiner, Alessandra Siegmann, Reinhard Golz, Stephan Störkel, Normann Willich, Axel Semjonow, Michael Stöckle, Christian Rübe, Udo Rebmann, Tilman Kälble, Horst Jürgen Feldmann, Manfred Wirth, Rainer Hofmann, Rita Engenhart-Cabillic, Axel Hinke, Wolfgang Hinkelbein, Kurt Miller European Urology Volume 66, Issue 2, Pages 243-250 (August 2014) DOI: 10.1016/j.eururo.2014.03.011 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram. HT=hormonal treatment; ITT=intent-to-treat; PSA=prostate-specific antigen. European Urology 2014 66, 243-250DOI: (10.1016/j.eururo.2014.03.011) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier plot of progression-free survival after radical prostatectomy (RP) with and without adjuvant radiotherapy in intent-to-treat patients who achieved an undetectable prostate-specific antigen after RP (ITT2). Bottom: Patients at risk in the wait-and-see or adjuvant radiotherapy trial arm. ART=adjuvant radiotherapy; PFS=progression-free survival; WS=wait-and-see. European Urology 2014 66, 243-250DOI: (10.1016/j.eururo.2014.03.011) Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 3 Forest plot for risk factors influencing the hazard ratio of progression-free survival in intent-to-treat patients who achieved an undetectable prostate-specific antigen after radical prostatectomy (ITT2) cohort with and without adjuvant radiotherapy. CI=confidence interval; neg.=negative; PFS=progression-free survival; pos.=positive; PSA=prostate-specific antigen; RP=radical prostatectomy. European Urology 2014 66, 243-250DOI: (10.1016/j.eururo.2014.03.011) Copyright © 2014 European Association of Urology Terms and Conditions